MRK  Merck & Company Inc.

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

170.1B

Vuru Grade

47.84/100

Current Price

$58.20
-0.385 (-0.66%)

Growth Price

$46.35
Overvalued by 20.35%

Stability Price

$23.07
Overvalued by 60.37%

Company Metrics

  • 38.64 P/E
  • 3.92 P/S
  • 3.43 P/B
  • 1.516 EPS
  • 10.80% Cash ROIC
  • 0.98 Cash Ratio
  • 1.75 / 2.99% Dividend
  • 8.83M Avg. Vol.
  • 2.92B Shares
  • 170.1B Market Cap.

Company Description

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company's Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, ...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Merck quarterly profit beats estimates; shares gain
Reuters - Jul 29, 2014
(Reuters) - Merck & Co Inc reported better-than-expected quarterly results on Tuesday, helped by strong sales of consumer products and medicines for arthritis and HIV, sending its shares up more than 1 percent in morning trading.
Earnings: UPS profit slides; Pfizer tops estimates; Merck doubles; Aetna ... - Newsday
Merck 2Q profit more than doubles - Sydney Morning Herald
Merck & Co., Inc. (MRK) Tops Q2 EPS by 5c
StreetInsider.com (subscription) - Jul 29, 2014
Merck & Co., Inc. (NYSE: MRK) reported Q2 EPS of $0.85, $0.05 better than the analyst estimate of $0.80. Revenue for the quarter came in at $10.93 billion versus the consensus estimate of $10.6 billion.
Merck & Co., Inc. (MRK) Releases FY14 Earnings Guidance - WKRB News
Merck & Co., Inc. Posts Higher Q2 Profits; Revenue Declines; Beats Estimates ... - Dividend.com
ETFs To Watch On Strong Earnings From Pharma Companies
ETF Daily News (blog) - 14 hours ago
Another chain of forecast-beating earnings from the industry primes like Pfizer (PFE), Merck (MRK), Eli Lilly and Company (LLY) and Bristol-Myers Squibb Company (BMY) is again building up confidence in the sector (read: Healthcare ETFs in Focus on JNJ ...
Merck & Co., Inc. (MRK) & Pfizer Inc. (PFE): Expectations For The Biopharma ...
ETF Daily News (blog) - 19 hours ago
Jim Bach: Two American pharmaceutical giants reported earnings this morning, both showing flagging sales - but one ended the day with a gain.
Pfizer leaves investors guessing on intentions for Astra - Chicago Tribune
Why Merck Is Heading To $65 (MRK)
Seeking Alpha (registration) - Jul 28, 2014
That and the fact that Merck is getting close to conducting Phase-3 trials for a combination treatment for Hepatitis C puts the company on the offense against Gilead Sciences (NASDAQ:GILD), which is the clear-cut market leader. The recent clinical data ...
Merck lays off 600 more employees at North Wales, Lansdale offices
The Times Herald - Jul 25, 2014
The Philadelphia Business Journal says the information comes from a Worker Adjustment and Retraining Notification (WARN) notice the pharmaceutical company filed with the Pennsylvania Department of Labor and Industry. Merck officials were not ...
Merck cutting 600 jobs - Albany Business Review (blog)
Earnings on Deck: Merck & Co., Inc., Level 3 Communications, Inc., and United ...
Schaeffers Research (blog) - Jul 28, 2014
This week's slate of quarterly earnings reports picks up the pace tomorrow when global health care concern Merck & Co., Inc. (NYSE:MRK), integrated communications specialist Level 3 Communications, Inc. (NYSE:LVLT), and industrial metals name United ...
Merck & Co., Inc. (MRK) Issues FY14 Earnings Guidance
Intercooler - Jul 30, 2014
Merck & Co. logo Merck & Co., Inc. (NYSE:MRK) updated its FY14 earnings guidance on Tuesday. The company provided EPS guidance of $3.43-3.53 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.48, American Banking ...
Merck ups earnings guidance after Q2 results (MRK)
Seeking Alpha (registration) - Jul 29, 2014
Merck (NYSE:MRK) Q2 results: Total Revenues: $10,934M (-0.7%), Pharmaceutical: $9,087M (-2.4%), Animal Health: $872M (+2.5%), Consumer Care: $583M (+19.0%), Other: $392M (+9.2%); Gross Profit: $6,041M (-10.2%); R&D Expense: $1,664M ...
Company Update: Merck & Co Inc (NYSE:MRK) – Merck CEO Karl-Ludwig Kley ...
Jutia Group - Jul 28, 2014
Merck & Co Inc (NYSE:MRK) [at noodls] - News Release Your Contact Gerhard Lerch Tel. 06151 72-6328 Nicole Mommsen Tel. 06151 72 62445 July 28, 2014 Merck CEO Karl-Ludwig Kley and German Federal Economics Minister Sigmar Gabriel ...